ZOMDF (Zomedica) Total Stockholders Equity: $110.95 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Zomedica Total Stockholders Equity?

Zomedica ZOMDF +2.27% Total Stockholders Equity is $110.95 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Zomedica's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $110.95 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Zomedica's Book Value per Share for the quarter that ended in Mar. 2026 was $0.11. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Zomedica's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.02.


Zomedica  (OTCPK:ZOMDF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Zomedica's Book Value per Share for the quarter that ended in Mar. 2026 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Zomedica's Debt-to-Equity for the quarter that ended in Mar. 2026 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zomedica Total Stockholders Equity Related Terms


Zomedica Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Zomedica's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zomedica Total Stockholders Equity Chart

Zomedica Annual Data
Trend Feb16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 270.89 267.39 240.02 195.66 115.40

Zomedica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.44 125.36 119.69 115.40 110.95
What does a Total Stockholders Equity of $110.95 Mil mean?
Zomedica (ZOMDF) has a Total Stockholders Equity of $110.95 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Zomedica and its competitors.
Is Zomedica's Total Stockholders Equity too high?
Zomedica's current Total Stockholders Equity is $110.95 Mil.
How does Zomedica's Total Stockholders Equity compare to SERA and HYPR?
Zomedica's Total Stockholders Equity of $110.95 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Zomedica and its competitors. Zomedica's current Total Stockholders Equity is $110.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zomedica stock overvalued right now?
Based on GuruFocus' analysis, Zomedica (ZOMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.19, compared to a current price of $0.09 — trading 52.6% below its estimated fair value. The current Total Stockholders Equity is $110.95 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Zomedica (ZOMDF), the current Total Stockholders Equity is $110.95 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zomedica Business Description

Address 1101 Technology Drive, Suite 100, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.